Member Info for The.Italian

well be i don't know anything about med500 but i can say quite categorically that the main reason ascribed by recodati for the poor showing of fortacin is the embarrassment factor,which they hope to address by moving from rx to oct.how successful this will be (assuming they get the required authority) only time will tell.i do take the point that in the internet age you might expect embarrassment not to be such a factor,but despite fortacin being marketed from 2018 onwards (not years ago) this does not appear to be the case.my point really i not to suggest how it is best marketed but just to make it clear that the issues may not be clear-cut and obvious.

fair points bucolic and you may well be right, but fortacin was only launched in 2018 (i think) so plenty of viagra experience by then.the problem with fortacin seems to have been poor market research and grossly overoptimistic estimates of users, which I'm sure FUM will avoid and i do accept that the sufferers' profiles are probably very different (which is one of the reasons i have invested in fum).

first I've changed the stupid heading and its infantile attempt to diminish any attempt to encourage grown up discussion by ascribing the term troll to anyone looking for that. second i and I'm sure others, completely understand the problems that could arise if fum fail to distinguish med 3000 from other otcs already available. my main point is that so far the RNSs issued by fum have placed emphasis on OTC.,which they have. no doubt before any decisions are reached extensive market research will be required.i have mentioned the problem of embarrassment factor. this militates towards OTC rather than prescription but i have no idea which route they may eventually decide to go down.in case anyone is in doubt as to the difficulties the embarrassment factor can cause,take the time to look at the history of fortacin produced by regent pacific (formerly plethora on aim )on the hk exchange. full ema authorisation for PE treatment and highly praised by the medical profession.sales so far in EU and associated territories virtually nil. its licensee recordati has now sought EMA approval to change from RX to OTC in the hope this will stimulate sales.the failure so far has been largely attributed to the embarrassment factor.now i completely accept that PE is different in kind from ED and that ED sufferers may be more wiling to undergo the embarrassment factor than PE sufferers, but it is still an important consideratio.so before you dismiss people because their views do not fit your agenda and attempt to do so by suggesting a lack of knowledge or intelligence,reflect upon the fact that there may actually be people who have far more knowledge of these matters the you, but may just choose not to indulge in your browbeating tactics.of one thing i am pretty certain the potential user numbers will be significantly overestimated ,although that does not mean the product will not be a success (i think it will)but expectations need to be realistic.

https://www.investopedia.com/ask/answers/nasdaq-listing-requirements/ doesn't look like we could comply with these at he moment.i wouldn't worry as listing on the nasdaq is not necessarily a passport to success.eg motif bio listed in 2016 and it was, i gather ,a disaster.expensive,with no real interest from us investors.obviously a very different type of company and i can see melody being suited to a nasdaq listing,but not yet.if it ever reached the point of being able to comply with the other listing requirement, the need for a minimum stock price unit can be met by aggregating the required number of shares into a larger unit with the required value.

i understand your reasoning Arturdeldia, but i don't get the impression that that is the route on which Fum are focussed.it could be, but the emphasis in the announcements has always seemed to be on OTC.i suppose we won't know until they have the first approval and are negotiating licence/distribution agreements.also of course it's a pricing issue as well as one of reach,so a lot for the marketeers to think about

well thats true bignose,but what im hoping for (hope not necessarily expectation) is that we can create at least some form of revenue stream, even if very modest,to help see us through the next couple of years without even more significant dilutionanyway one step at a time.lets make sure we get formal eu approval first.

not according to the 14th july RNS update.fum expect to provide an update on the eu application at the time of their interims in september, this is what the but continue to target a 2021 approval date.no chance of approval within next couple of months I'm afraid, but early next year is possible it seems.

ok A1ex.good idea.very interested to see what they say.

i assume that if there had been a spike in the s/p because of the rumour (something fairly substantial ) melody would have had to comment.whilst it remains just a rumour with no appreciable effect on s/p i wouldn't expect them to comment.just my opinion.

no there was a similar spike on no news which took us to i think 26p before falling back.the only news still expected this month now is a possible update on the cbd tie up, but thats very early stage so not, imo, potentially a catalyst for any significant rise.

yes could well explain the uplift.will be interesting to see what happens when the update is issued.fingers crossed.

not sure about sensitivity but assume its ok to say reply immediately to my email ,confirming CHMP made positive recommendation to european commission yesterday.now down to commission to approve which is expected about 23rd september.an operations update is to be issued, so more information to follow. from memory i think the formal commission approval is pretty much a formality after the recommendation but i could be wrong.anyway excellent news imo,although don't want to get carried way.we still don't know how it will sell in new guise but i think its a very important step,assuming it all goes through.

https://www.udiscovermusic.com/news/nelly-country-grammar-live-entirety/ apologies if this has already been posted.it does give details of how long the youtube full concert will be available after the live performance which i don't recall having seen before but i may have missed them.

apologies. mistyped it .its 13p and exercisable within 12 months of fundraise, so 4th may 2021 or thereabouts

agree albert. i don't think it is anything to do with brixton. i expect a full lineup announcement soon(?) from live nation not piecemeal.just my opinion of course/.
.

may be relevant to mention that the fundraise warrants referred to inRNS of 4th may have an exercise price of 15p

quite correct GLA. another share I'm interested in is the subject of a CHMP committee meeting consideration, which has taken place during the first 4 days of this week.meetings are taking place remotely etc.not saying there hasn't been some disruption but this type of meeting has been carrying in accordance with its normal scheduling.

very interesting quote keith .one to bear in mind imo.

no cannot get a quote to buy even a couple of hundred pounds worth.

agree the acronym CHMP does rather lend itself!